thalidomide has been researched along with Tumour Lysis Syndrome in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide was safely titrated to 20 mg/day; the MTDEL was not reached." | 2.77 | Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. ( Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maddocks, K | 1 |
| Wei, L | 1 |
| Rozewski, D | 1 |
| Jiang, Y | 1 |
| Zhao, Y | 1 |
| Adusumilli, M | 1 |
| Pierceall, WE | 1 |
| Doykin, C | 1 |
| Cardone, MH | 1 |
| Jones, JA | 1 |
| Flynn, J | 1 |
| Andritsos, LA | 1 |
| Grever, MR | 1 |
| Byrd, JC | 1 |
| Johnson, AJ | 1 |
| Phelps, MA | 1 |
| Blum, KA | 1 |
| Chanan-Khan, AA | 2 |
| Whitworth, A | 1 |
| Bangia, N | 1 |
| Porter, CW | 1 |
| Lee, K | 1 |
| Wendtner, CM | 1 |
| Hillmen, P | 1 |
| Mahadevan, D | 1 |
| Bühler, A | 1 |
| Uharek, L | 1 |
| Coutré, S | 1 |
| Frankfurt, O | 1 |
| Bloor, A | 1 |
| Bosch, F | 1 |
| Furman, RR | 1 |
| Kimby, E | 1 |
| Gribben, JG | 1 |
| Gobbi, M | 1 |
| Dreisbach, L | 1 |
| Hurd, DD | 1 |
| Sekeres, MA | 1 |
| Ferrajoli, A | 1 |
| Shah, S | 1 |
| Zhang, J | 1 |
| Moutouh-de Parseval, L | 1 |
| Hallek, M | 1 |
| Heerema, NA | 1 |
| Stilgenbauer, S | 1 |
| Fuente, N | 1 |
| Mañe, JM | 1 |
| Barcelo, R | 1 |
| Muñoz, A | 1 |
| Perez-Hoyos, T | 1 |
| Lopez-Vivanco, G | 1 |
| Lee, CC | 1 |
| Wu, YH | 1 |
| Chung, SH | 1 |
| Chen, WJ | 1 |
| Huston, A | 1 |
| Brown, J | 1 |
| Roodman, GD | 1 |
| Chim, CS | 1 |
| Moutouh-de Parseval, LA | 1 |
| Weiss, L | 1 |
| DeLap, RJ | 1 |
| Knight, RD | 1 |
| Zeldis, JB | 1 |
| Cany, L | 1 |
| Fitoussi, O | 1 |
| Boiron, JM | 1 |
| Marit, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia[NCT00419250] | Phase 1 | 52 participants (Actual) | Interventional | 2006-12-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Tumour Lysis Syndrome
| Article | Year |
|---|---|
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort S | 2015 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic | 2012 |
7 other studies available for thalidomide and Tumour Lysis Syndrome
| Article | Year |
|---|---|
Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, | 2008 |
Tumor lysis syndrome in a multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Tumor Lysis Syndrom | 2004 |
Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Thal | 2006 |
Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Immu | 2006 |
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tu | 2007 |
Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma.
Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Multiple Myeloma; Thalidomide; Tumor Lysis Syndr | 2002 |